Skip to main content
Clinical Trials/NCT04537104
NCT04537104
Unknown
N/A

Investigating Arrhythmias in a High-risk Population With Heart Failure Using Remote Monitoring (Coala Heart Monitor)

Herlev and Gentofte Hospital1 site in 1 country130 target enrollmentSeptember 24, 2020
ConditionsHeart Failure

Overview

Phase
N/A
Intervention
Not specified
Conditions
Heart Failure
Sponsor
Herlev and Gentofte Hospital
Enrollment
130
Locations
1
Primary Endpoint
New-onset arrhythmias
Last Updated
5 years ago

Overview

Brief Summary

This study is a prospective cohort study with consecutive enrollment of newly diagnosed heart failure patients, investigating the prevalence and types of arrhythmias in this high-risk population using non-invasive remote monitoring with the Coala Heart Monitor. Participants are scheduled to use the Coala Heart Monitor twice daily or during symptoms (e.g. syncope, presyncope, palpitations, chest discomfort, or shortness of breath) to record a thumb and chest ECG over 3 months. Patient compliance with the recordings, self-reported health, response to technology, and experience using the device will additionally be assessed by self-developed questionnaires and the Kansas City Cardiomyopathy Questionnaire (KCCQ) at 3 months.

Registry
clinicaltrials.gov
Start Date
September 24, 2020
End Date
September 1, 2023
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Morten Lamberts

Associate Professor and Research Director

Herlev and Gentofte Hospital

Eligibility Criteria

Inclusion Criteria

  • Owns or has access to a smartphone
  • Newly diagnosed moderate to severe heart failure (NYHA II-IV and left ventricular ejection fraction ≤ 40%)

Exclusion Criteria

  • Earlier atrial fibrillation/atrial flutter with indication for oral anticoagulant (OAC) treatment
  • Pacemaker
  • Cardiac resynchronization device
  • Indications for OAC treatment (also low molecular weight heparin) due to atrial arrhythmias, mechanical heart valve, deep vein thrombosis, or pulmonary embolism.
  • Expected survival ≤ 6 months
  • Absolute contraindications for starting OAC treatment

Outcomes

Primary Outcomes

New-onset arrhythmias

Time Frame: 3 months

Incidence of newly diagnosed atrial fibrillation/atrial arrhythmias on patient-activated thumb and chest ECG recordings

Secondary Outcomes

  • Patient compliance(Week 8)
  • Patient-reported outcomes(3 months)
  • Subsequent implantations(3 years)
  • Patient self-reported health(3 months)
  • Admissions for worsening heart failure(3 years)
  • Subsequent prescriptions(3 years)
  • Assessing recordings(3 months)
  • Cardiovascular mortality(3 years)
  • Subsequent readmissions(3 years)
  • All-cause mortality(3 years)

Study Sites (1)

Loading locations...

Similar Trials